Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Aspirin led the generics with the fastest-rising UK prices in June, according to the latest figures from WaveData.
Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.
Bupa Arabia for Cooperative Insurance believes savings of up to 40% per year could be achieved if Saudi Arabia opted for legislation to drive uptake of generic medicines.
Australia has reaped the rewards of outreach efforts on biosimilars, according to the country’s GBMA off-patent industry association, with the market share enjoyed by biosimilar medicines rising significantly in the two years since Australia’s government issued a grant for educational activities. In future, the GBMA’s Biosimilar Awareness Week could be used as the model for a global biosimilars campaign backed by the IGBA.
Exemestane led the steepest price rises for generics seen in the UK in May. However, concession pricing for the breast cancer drug overestimated the actual prices in the market recorded by WaveData.
Erythromycin and paracetamol were among the products with the steepest price rises in the UK in April, as the coronavirus pandemic continued to make its effects felt in the generics market.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.